乌美溴铵/维兰特罗在中国患者真实世界中的安全性研究
该研究为24周前瞻性、多中心、单臂观察性研究,纳入中国14家中心887例使用乌美溴铵/维兰特罗的患者,主要评估不良事件和严重不良事件发生率。结果显示不良事件发生率为6.7%,严重不良事件为2.4%,均与药物无关,药物不良反应仅0.7%且均为轻度。结论认为该药在中国真实世界人群中耐受性良好,未发现新的安全性信号。
要点
- 中国真实世界研究中乌美溴铵/维兰特罗不良事件发生率6.7%,多为轻中度。
- 严重不良事件发生率2.4%,包括致死性事件,经判定均与药物无关。
- 药物不良反应仅0.7%,均为轻度,未观察到新的安全性信号。
核心结论
- 乌美溴铵/维兰特罗在中国真实世界人群中耐受性良好,未观察到新的药物相关安全性信号。
研究设计与样本
- 前瞻性、多中心、单臂、观察性研究,中国14家中心,2020年12月14日至2022年1月30日入组,随访24周。
- 共纳入887例接受乌美溴铵/维兰特罗治疗的患者,平均年龄67.5±9.6岁,男性77.7%。
主要发现
- 98.1%患者有慢性阻塞性肺疾病史,67.6%报告合并症,52.8%使用合并药物。
- 59例(6.7%)报告不良事件,多为轻中度;21例(2.4%)报告严重不良事件,其中9例致死性、10例非致死性、2例两者均有。
- 所有严重不良事件经研究者判定均与乌美溴铵/维兰特罗无关。
- 6例(0.7%)报告药物不良反应,均为轻度;3例(0.3%)报告的不良事件属于重要已确定或潜在风险,均判定与药物无关。
临床怎么用
- 在中国真实世界人群中,乌美溴铵/维兰特罗的安全性数据支持其用于慢性阻塞性肺疾病患者。
- 用药期间需关注不良事件,但严重不良事件与药物的因果关系经判定均不相关。
局限性
- 单臂观察性研究,无对照组,无法比较相对安全性。
- 随访24周,长期安全性数据有限。
- 纳入人群以男性为主(77.7%),可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the safety of umeclidinium/vilanterol in Chinese participants in a real-world setting. Methods: This was a 24-week, prospective, multicenter, single-arm, observational study that enrolled participants treated with umeclidinium/vilanterol in real-world settings from 14 sites in China from 14 December 2020 to 30 January 2022. The primary outcomes were the incidence of adverse events (AEs) and serious adverse events (SAEs) at week 24. Results: A total of 887 participants on umeclidinium/vilanterol were enrolled. The mean (±SD) age of these participants was 67.5 (±9.6) years, with more men (77.7%) enrolled. The majority of the participants (98.1%) had been diagnosed with chronic obstructive pulmonary disease, and 67.6% of them reported comorbidities. More than half of the participants (52.8%) were taking concomitant medication in addition to the study treatment. AEs were reported in 59 (6.7%) participants and were predominantly mild to moderate in severity. SAEs were reported in 21 (2.4%) participants, including 9 fatal SAEs, 10 reported non-fatal SAEs, and 2 reported both non-fatal and fatal SAEs. None of the SAEs, including the fatal events, were considered by the investigators to be related to umeclidinium/vilanterol. Adverse drug reactions (ADRs) were reported in 6 (0.7%) participants with 4 preferred terms (PTs), all of which were considered mild in severity. Of these PTs, 2 were known ADRs of umeclidinium/vilanterol. Three participants (0.3%) reported AEs that were part of serious identified/potential hazards, all of which were considered by the investigators to be unrelated to umeclidinium/vilanterol. Conclusion: The results of this study showed that umeclidinium/vilanterol was well tolerated in Chinese participants in a real-world setting and no new drug-related safety signals were observed. 目的: 评估乌美溴铵/维兰特罗在真实世界临床实践中应用于中国患者的安全性。 方法: 采用前瞻性、多中心、单臂、观察性研究,在2020年12月14日至2022年1月30日,从中国的14家研究中心纳入在真实世界临床实践中接受乌美溴铵/维兰特罗治疗的患者,共随访24周。研究主要结局为随访期内不良事件和严重不良事件的发生率。 结果: 共纳入887例患者,年龄为(67.5±9.6)岁,其中男性689例(77.7%)。大多数患者(98.1%)有慢性阻塞性肺疾病史。468例患者(52.8%)报告了合并药物。在所有纳入的患者中,59例(6.7%)报告了不良事件,21例(2.4%)报告了严重不良事件,其中9例报告了致死性严重不良事件,10例报告了非致死性严重不良事件,2例同时报告了非致死性和致死性严重不良事件。所有严重不良事件,包括致死性事件,经研究者判定均与乌美溴铵/维兰特罗无关。6例(0.7%)发生药物不良反应,其严重程度均为轻度。3例(0.3%)患者报告的不良事件属于重要已确定或潜在风险,经研究者判定均与乌美溴铵/维兰特罗无关。 结论: 乌美溴铵/维兰特罗在真实世界临床实践中应用于中国患者具有良好的安全性,未观察到与该药相关的新的安全性信号。.
引用
- Mu XD, Li XM, He XP, et al. [Safety of umeclidinium/vilanterol in Chinese patients in a real-world setting: a prospective, multicenter, single-arm, observational study]. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38955748. doi:10.3760/cma.j.cn112147-20231124-00339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。